Rockefeller Capital Management L.P. Actinium Pharmaceuticals, Inc. Transaction History

Rockefeller Capital Management L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.15 - $9.39 $8,508 - $11,174	-1,190 Reduced 7.47%	14,733 $109,000
Q1 2023 May 17, 2023	BUY	$8.51 - $14.26 $7,165 - $12,006	842 Added 5.58%	15,923 $150,000
Q4 2022 Mar 06, 2023	BUY	$7.05 - $14.41 $5,287 - $10,807	750 Added 5.23%	15,081 $160,000
Q3 2022 Nov 02, 2022	BUY	$4.81 - $8.48 $6,974 - $12,296	1,450 Added 11.26%	14,331 $105,000
Q2 2022 Aug 12, 2022	BUY	$4.71 - $7.11 $4,710 - $7,110	1,000 Added 8.42%	12,881 $61,000
Q1 2022 May 13, 2022	BUY	$4.57 - $6.4 $15,995 - $22,400	3,500 Added 41.76%	11,881 $60,000
Q3 2021 Nov 12, 2021	BUY	$5.76 - $9.67 $8,640 - $14,505	1,500 Added 21.8%	8,381 $74,000
Q1 2021 May 11, 2021	BUY	$7.62 - $9.79 $23,629 - $30,358	3,101 Added 82.04%	6,881 $52,000
Q4 2020 Feb 12, 2021	BUY	$7.8 - $12.64 $13,080 - $21,197	1,677 Added 79.74%	3,780 $29,000
Q3 2020 Nov 13, 2020	BUY	$7.26 - $18.0 $15,267 - $37,854	2,103 New	2,103 $20,000

8.31M

65.2K

21.7K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $28.2M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.